The first hematopoietic transplant in which umbilical cord blood (UCB) was used as the
source of hematopoietic cells was performed in October 1988. Since then, significant …

Unrelated donor cord blood transplantation (CBT) results in disease-free survival
comparable to that of unrelated adult donor transplantation in patients with hematologic …

Clinical application of umbilical cord blood (UCB) as a source of hematopoietic stem cells for
transplantation is limited by low CD34+ cell dose, increased risk of graft failure, and slow …

Now available in a thoroughly revised Twelfth Edition, Wintrobe's Clinical Hematology
continues to be an industry leader with its ability to correlate basic science with the clinical …

Precise and efficient manipulation of genes is crucial for understanding the molecular
mechanisms that govern human hematopoiesis and for developing novel therapies for …

The glycosciences aim to understand the impact of extracellular and intracellular
carbohydrate structures on biological function. These glycans primarily fall into three major …

Umbilical cord blood (CB) is a rich source of hematopoietic stem cells (HSCs) with important
applications in allogeneic stem cell transplantation. However, the low numbers of …

Allogeneic hematopoietic cell transplantation (HCT) provides the best chance for cure for
many patients with malignant and nonmalignant hematologic disorders. Recent advances in …

Transplantation of 2 unrelated cord blood (UCB) units instead of 1 has been proposed to
increase the cell dose. We report a prospective randomized study, designed to compare …

Transplantation of umbilical cord blood (UCB) is an attractive alternative source of
hematopoietic stem cells (HSCs). The unique properties of cord blood and its distinct …